Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amiodarone + propranolol
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy of amiodarone (a class III antiarrhythmic) and propranolol (a nonselective beta-blocker) used primarily for treating life-threatening and drug-resistant cardiac arrhythmias. Amiodarone blocks potassium currents during cardiac repolarization, while propranolol blocks beta-adrenergic receptors. When used together, they demonstrate synergistic effects in controlling tachyarrhythmias, particularly in cases where amiodarone alone is insufficient.
02
Targets
KCNH2 (Voltage-gated potassium channel subfamily H member 2)SCN5A (Sodium channel protein type 5 subunit alpha)ADRB1 (β1)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on amiodarone + propranolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amiodarone + propranolol.